Skip to content
Review

Alzheimer's Disease (AD) Neuroinflammation and Excitotoxicity: Mechanisms and New Treatment Approaches

Sep 2026 · Current Chemical Biology · Vol 20 · 0 citations

TL;DR

Key results show that using anti-inflammatory drugs and therapies that support calcium balance can effectively interrupt the pathological cycle between neuroinflammation and excitotoxicity, and Simultaneously targeting multiple interconnected pathogenic pathways is a promising therapeutic strategy for reducing neurodegeneration, maintaining cognitive function, and delaying the onset of dementia.

Abstract

According to the World Health Organization, Alzheimer's Disease (AD) is an escalating global health crisis that requires more study and better diagnostic methods, with dementia cases projected to reach 131 million by 2050. Widespread neuroinflammation is central to the pathophysiological pathways of AD, a complex neurodegenerative disease. Microglia are activated by tau protein phosphorylation and amyloid-beta plaque formation, which starts the neuroinflammatory process. Reactive Oxygen Species (ROS) and other inflammatory mediators, such as cytokines, are released by activated microglia and can start a feed-forward cycle that exacerbates brain injury and cell death. Excitotoxicity also results in mitochondrial dysfunction and oxidative stress, both of which lead to neuronal death. Dysregulated glutamate signaling mediates this. This review aims to evaluate innovative therapeutic strategies targeting neuroinflammatory and excitotoxic pathways. One of the innovative ways to enhance neuroprotection and reduce oxidative damage at the same time is to alter microglial activation. Anti-inflammatory treatments, such as Non-Steroidal Anti-Inflammatory medications (NSAIDs), and treatments that target the inflammasome and Tumor Necrosis Factor-alpha (TNF-α) pathways are meant to alleviate chronic inflammation. In order to prevent neurodegeneration, the treatment of excitotoxicity aims to maintain calcium homeostasis and regulate glutamate. A systematic literature search was conducted across the electronic databases, including PubMed, Scopus, ScienceDirect, Web of Science, and Google Scholar, covering the period from 1991 to 2025. Keywords used included "Alzheimer’s disease," "neuroinflammation," "microglial activation," "excitotoxicity," and "kinase inhibitors." Studies were selected based on inclusion criteria focused on molecular mechanisms and clinical/pre-clinical therapeutic interventions. A total of 136 relevant peerreviewed articles and clinical trial reports were retrieved for this review. These key results show that using anti-inflammatory drugs and therapies that support calcium balance can effectively interrupt the pathological cycle between neuroinflammation and excitotoxicity. To take care of patients and find new ways to treat them without harming their neurons, we need to do more research. Simultaneously targeting multiple interconnected pathogenic pathways is a promising therapeutic strategy for reducing neurodegeneration, maintaining cognitive function, and delaying the onset and progression of dementia.

View source

Similar papers

Open access Oct 2026

"Pharmacological Modulation of Neuroinflammation in Alzheimer's Disease: Current Advances, Emerging Therapeutic Targets, and Future Perspectives"

The gradual degeneration of brain cells, known as synapses and neurones, is the main cause of memory loss and cognitive dysfunction in Alzheimer's disease (AD), a neurodegenerative disorder. Chronic neuroinflammation is an important factor in the development and advancement of the illness, with characteristic pathologi...

Vaishnavi Vijay, Patil, Vaishnavi Mahesh Patil et al. · 0 citations
Review Oct 2026

Neuroinflammation in Alzheimer's disease: From glial cell states and molecular networks to biomarkers and precision therapeutics.

Alzheimer's disease (AD) is now recognized as a biologically heterogeneous syndrome in which amyloid-β pathology, Tau-related alterations, and neuroinflammation are key interconnected processes. Microglia, astrocytes, oligodendrocytes, complement, inflammasomes, neurovascular cells, and peripheral immunity are implicat...

Priyanka Samantaray, Poonam Verma · 0 citations
Review Open access Sep 2026

The Role of Neuroinflammation in Alzheimer's Disease: Molecular Mechanisms and Emerging Therapeutic Approaches

This review examines the molecular and cellular mechanisms through which neuroinflammation contributes to the progression of AD, with particular emphasis on microglial activation, TREM2 and soluble TREM2 (sTREM2) signaling, NLRP3 inflammasome activation, astrocyte–microglia interactions, and blood–brain barrier dysfunc...

Shreyansh Goswami · 0 citations
Review Sep 2026

Crosstalk and Convergence in Alzheimer's Disease: Integrating Brain Injury, Neuroinflammation, and Precision Medicine for Next-Generation Therapeutics.

This review proposes conceptualizing Alzheimer's disease as a neural circuit disorder that emerges from sustained crosstalk among multiple interacting pathways, including brain injury, neuroinflammation, mitochondrial and metabolic dysfunction, neurovascular dysfunction, neurovascular dysfunction, synaptic dysfunction,...

Desh Deepak Singh · 0 citations
Review Sep 2026

Targeting cytokine-driven neuroinflammation in Alzheimer’s disease: mechanistic insights and pharmacological strategies

This review provides a comprehensive overview of cytokine-mediated neuroinflammation in Alzheimer's disease, focusing on the cellular sources of cytokine production within the brain, including microglia, astrocytes, neurons, and endothelial cells.

R. Wasim · 0 citations
Review Open access Sep 2026

Inflammasomes: central mediators of neuroinflammatory neurodegeneration in Alzheimer’s and Parkinson’s disease

As life expectancy increases worldwide, the proportion of people aged 65 and older is expected to double by 2050 and these global demographic shifts will be accompanied by an increase in age-related neurodegenerative diseases such as Alzheimer’s (AD) and Parkinson’s disease (PD). AD is the leading cause of dementia w...

C. Tropis, Janna Jernigan Posey, M. Tansey et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.